What were the main results of the study?
More than half of the participants (53.2%) had undergone genotypic resistance testing when they were diagnosed with HIV. Over time, the proportion of people undergoing genotyping testing rose from 30.0% in 2002 to 82.6% in 2009.
Nearly 14% of all PHAs who had their HIV tested had one or more drug-resistant mutations. There were different resistance patterns found among the HIV tested. The proportions of drug resistance were as follows: • 8.8% conferred resistance to nucleoside/tide reverse transcriptase inhibitors (NRTIs); • 4.8% conferred resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs); and, • 2.7% conferred resistance to protease inhibitors.
Drug resistance increased over time, with PHAs diagnosed in 2008-09 being 8 times more likely to have NNRTI resistance and 4 times more likely to have NRTI resistance, compared to PHAs diagnosed in 2002-07. .
What do the study results mean for the treatment and care of people living with HIV?
PHAs who have not started on antiretroviral treatment will benefit from knowing if they may be infected with a resistant strain of HIV. Selecting treatment based on drug resistance testing leads to better treatment outcomes and it is more cost-effective.
Where can I find the full-length publication of this study?
This study was published in the Journal of Antimicrobial Chemotherapy. The full text version is available at: http://jac.oxfordjournals.org/content/67/11/2755.
The Ontario HIV Treatment Network Cohort Study (OCS)
is an ongoing research study that collects clinical, social and behavioural information about people living with HIV (PHA) in Ontario. Participation in the study is voluntary, and all personally identifying information of study participants is removed to ensure confidentiality. The OCS was established to improve our understanding of HIV and to inform HIV prevention, care and treatment strategies for people living with HIV and groups at increased risk of HIV infection. For more information about the OCS, please contact the OCS Research Coordinator, Brooke Ellis at: bellis@ohtn.on.ca.
